Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCLL.L Regulatory News (CLL)

  • There is currently no data for CLL

Launch of CSR programme

13 Mar 2012 07:00

RNS Number : 2001Z
Cello Group plc
13 March 2012
 



13 March 2012

 

Cello Group plc

 

Launch of CSR programme

 

Cello Group plc (AIM:CLL, 'Cello', or 'the Group'), the insight and strategic marketing group, has today launched its new Corporate Social Responsibility programme 'Talking Taboos'. 

 

Talking Taboos is a campaigning brand that aims to directly tackle health and social issues using Cello's experience and resources in the healthcare space. It will focus on areas where embarrassment, fear or ignorance prevents sufferers from seeking help.

 

For 2012, Talking Taboos will be addressing teen mental health, specifically self-harm, through an extensive research project with the teen charity YoungMinds. The research will examine the context in which teenagers find themselves when actively self-harming, and will attempt to inform parents, teachers, peers and health professionals how best to identify and support at-risk and self-harming teens.

Each Cello Group company will utilise its expertise in methodology or market sector to contribute to a 'whole community' view that will help carers and sufferers by providing context, exploding myths and challenging prevailing attitudes to self-harm. The programme is being led by Vincent Nolan, Group Chairman of Cello Research and Consulting, and the Group is planning to expand this initiative in the future to assist organisations which address a range of health related issues.

Mark Scott, Cello Group CEO, said:

 

"Talking Taboos is a great opportunity for us to support a worthwhile cause in the best way we know how - through our market leading research and our wealth of experience in working with health issues.

 

"It is also an ideal way for our companies to demonstrate their abilities and talents and work across the group to deliver a comprehensive project that should help change the way that self-harm is perceived and handled."

 

 

Enquiries:

 

Cello Group plc (www.cellogroup.com)

Mark Scott, Chief Executive

020 7812 8460

Mark Bentley, Group Finance Director

Vincent Nolan, Group Chairman - Cello Research and Consulting

020 7655 9900

Cenkos

Bobbie Hilliam

020 7397 8900

College Hill

Kay Larsen/Rozi Morris

020 7457 2020

 

 

Notes to Editors (www.cellogroup.com)

 

Cello is an insight and strategic marketing group.

 

The Group's strategy is to create value for shareholders by building an international research and consulting business able to advise blue chip clients globally, along with a marketing business capable of delivering world class solutions.

 

Cello has annualised revenues in excess of £130m, annualised gross profit in excess of £65m and employs over 700 professional staff.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAGGUUWWUPPGMP
Date   Source Headline
2nd Oct 20198:40 amRNSDisposal
18th Sep 20197:00 amRNSInterim Results
23rd Aug 201910:40 amRNSHolding(s) in Company
16th Aug 20197:00 amRNSAcquisition of ISS
6th Aug 20193:07 pmRNSTotal Voting Rights
6th Aug 20197:00 amRNSNotification of Half Year Results
18th Jul 20197:00 amRNSPre-close Trading Update
20th Jun 20194:29 pmRNSDirector/PDMR Shareholding
10th Jun 20199:41 amRNSTotal Voting Rights
24th May 201912:45 pmRNSBlock listing Interim Review
20th May 20194:29 pmRNSIssue of Equity
15th May 20197:00 amRNSHolding(s) in Company
8th May 20191:30 pmRNSResult of AGM
8th May 20197:00 amRNSAGM Statement
1st May 201912:15 pmRNSTotal Voting Rights
15th Apr 201911:12 amRNSAnnual Report and Notice of AGM
10th Apr 20197:00 amRNSCapital Markets Event
4th Apr 201910:00 amRNSTotal Voting Rights
27th Mar 20191:00 pmRNSHolding(s) in Company
21st Mar 20193:10 pmRNSDirector/PDMR Shareholding
21st Mar 20197:00 amRNSPreliminary Results
6th Mar 20191:51 pmRNSHolding(s) in Company
7th Feb 20197:00 amRNSNotice of Full Year Results
17th Jan 20197:00 amRNSPre-Close Trading Statement
14th Dec 20189:24 amRNSBlock Listing Update
23rd Nov 20183:45 pmRNSHolding(s) in Company
19th Nov 20182:45 pmRNSHolding(s) in Company
12th Nov 201811:30 amRNSDirectorate Change
5th Nov 20182:00 pmRNSDirectorate Change
31st Oct 20183:30 pmRNSDirector/PDMR Shareholding
10th Oct 20187:00 amRNSDirector/PDMR Shareholding
2nd Oct 20187:00 amRNSAppointment of Executive Director
25th Sep 20181:00 pmRNSDirector/PDMR Shareholding
25th Sep 20187:00 amRNSDirector/PDMR Shareholding
24th Sep 201811:39 amRNSTransfer of FTSE classification to Healthcare
21st Sep 201810:15 amRNSDirector/PDMR Shareholding
20th Sep 20184:00 pmRNSHolding(s) in Company
20th Sep 20187:00 amRNSDirector/PDMR Shareholding
19th Sep 20187:00 amRNSInterim Results
22nd Aug 20181:51 pmRNSHolding(s) in Company
17th Aug 20187:00 amRNSNotification of Half Year Results
16th Aug 20182:00 pmRNSTotal Voting Rights
16th Aug 20181:30 pmRNSBoard Changes
23rd Jul 20187:00 amRNSHolding(s) in Company
19th Jul 20187:00 amRNSPre-close Trading Update
17th Jul 20187:00 amRNSChange of registered office
4th Jul 20181:53 pmRNSHolding(s) in Company
27th Jun 201812:46 pmRNSHolding(s) in Company
22nd Jun 20184:47 pmRNSHolding(s) in Company
20th Jun 20182:25 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.